Los Angeles Capital Management
NUVB icon

Los Angeles Capital Management’s Nuvation Bio NUVB Stock Holding History

Los Angeles Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.25K Sell
2,157
-50,116
-96% -$279K ﹤0.01% 1972
2025
Q4 		$269K Sell
52,273
-53,747
-51% -$333K ﹤0.01% 1132
2025
Q3 		$392K Hold
106,020
– – ﹤0.01% 1022
2025
Q2 		$207K Buy
+106,020
New +$221K ﹤0.01% 1187

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Los Angeles Capital Management's NUVB Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Nuvation Bio (NUVB) stake by 96% in Q1 2026, selling an estimated $279K and leaving 2,157 shares worth $9.25K. The position accounts for ﹤0.01% of the portfolio, ranked #1972.

Los Angeles Capital Management first reported a position in NUVB in Q2 2025 and has held it in 4 quarters since. The position peaked at $392K in Q3 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Los Angeles Capital Management held 2,157 shares of Nuvation Bio worth $9.25K as of Q1 2026.
  • Los Angeles Capital Management sold 50,116 Nuvation Bio shares in Q1 2026, an estimated $279K.
  • Nuvation Bio made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1972 holding.
  • Los Angeles Capital Management first reported a position in Nuvation Bio in Q2 2025 and has held it in 4 quarters since.
  • Los Angeles Capital Management's Nuvation Bio position peaked at $392K in Q3 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.